After careful consideration, the Board of Directors of Medicenna determined that it is in the overall best interests of the Company not to appeal Nasdaq’s delisting decision and delist its common shares from Nasdaq. The Board’s decision was based on several factors, including the continuing volatility of the financial markets in the life science sector and, accordingly, in the Company’s current share price and market value, and an analysis of the benefits of continued listing on Nasdaq weighed against the regulatory burdens and costs associated with maintaining such listing. The Company anticipates significant financial savings as a result of this decision. With the common shares concurrently trading on the TSX, the Company believes that the significant costs associated with a continued Nasdaq listing, as well as the administrative burdens and extensive amount of management’s time, attention and resources expended on regulatory compliance to maintain a Nasdaq listing, are not justified at this time. Following the delisting of the Company’s common shares on the Nasdaq, the Company will also seek to have its common shares traded on the OTC Markets as soon as possible thereafter. Nasdaq has notified the Company that trading of its common shares will be suspended as of the opening of business on November 2, 2023, and a Form 25-NSE will be filed with the United States Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDNA:
- Medicenna Announces Nasdaq Delisting and Cutback of Management Team
- Medicenna doses first patient in Phase 2 dose expansion of Phase 1/2 ABILITY
- Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
- Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
- Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer